Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29219624 | 0.94 | AKT1 (0.37) | AKT1USP2CTSSPTGES | |
| SCHEMBL30541442 | 0.94 | AKT1 (0.37) | AKT1USP2CTSSPTGES | |
| SCHEMBL29219622 | 0.94 | AKT1 (0.37) | AKT1USP2CTSSPTGES | |
| SCHEMBL13120902 | 0.93 | KMT2A (0.39) | AKT1USP2MEN1KMT2AALOX5 | |
| SCHEMBL30541490 | 0.93 | KMT2A (0.39) | AKT1USP2MEN1KMT2AALOX5 | |
| SCHEMBL29219958 | 0.93 | KMT2A (0.39) | AKT1USP2MEN1KMT2AALOX5 | |
| SCHEMBL29219956 | 0.93 | KMT2A (0.39) | AKT1USP2MEN1KMT2AALOX5 | |
| SCHEMBL5862048 | 0.89 | MEN1 (0.42) | RIPK1CTSSMEN1KMT2APTGES | |
| SCHEMBL6092925 | 0.89 | MEN1 (0.42) | RIPK1CTSSMEN1KMT2APTGES | |
| SCHEMBL6092928 | 0.89 | MEN1 (0.42) | RIPK1CTSSMEN1KMT2APTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447090-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | GUCY1A1, PDE2A, GUCY1A2 | AKT1 465/4885USP2 2918/4885RIPK1 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.